Fairvalue-Calculator Fairvalue-Calculator
EN DE

EVE Health Group (EVE) Fair Value & Analysis

Consumer Defensive · AU · Market cap A$8.4M

PriceA$0.0200
Fair ValueA$0.0200
Upside+0.0%
Quality95/100
Evidence: Low Range A$0.0180 – A$0.0220

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

EVE Health Group (EVE) currently trades at A$0.0200, while our model-based Fair Value estimate is A$0.0200 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was formerly known as EVE Investments Limited. EVE Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.

Open the full interactive analysis →

Similar stocks

Nestlé S.A (NESN) -29% Foshan Haitian Flavouring and Food Company (603288) -28% Nestlé India Limited (NESTLEIND) -75% Grupo Bimbo, S.A. (BIMBOA) +46% Uni-President Enterprises Corp (1216) -27% Britannia Industries Limited (BRITANNIA) -62%

Frequently asked questions

Is EVE Health Group (EVE) undervalued?
As of Jun 26, 2026, our model estimates a fair value of A$0.0200 versus a price of A$0.0200 — about +0% (undervalued). Model-based estimate, not financial advice.
What is the fair value of EVE?
Our 21-model fair value for EVE Health Group is A$0.0200 (as of Jun 26, 2026), built from audited fundamentals. The current price is A$0.0200.
What is the quality score of EVE?
EVE Health Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.